Telix's TLX591-Tx Shows Strong Patient Selection Data in Prostate Cancer Study — Telix Pharmaceuticals Limited

Event summary

Telix's ProstACT SELECT study results published in Cancers journal confirm the utility of 68Ga-PSMA-PET imaging for patient selection using a theranostic approach.
TLX591-Tx demonstrated a median radiographic progression-free survival (rPFS) of 8.8 months in evaluable patients with advanced metastatic prostate cancer.
The study highlighted TLX591-Tx’s differentiated clinical profile, including an intensified dosing schedule and low salivary gland irradiation.
TLX591-Tx is currently being evaluated in the international multi-center Phase 3 ProstACT Global study.

The big picture

Telix's publication in Cancers journal underscores the growing importance of theranostics in precision oncology, particularly for advanced prostate cancer. The study results strengthen Telix's position as a key player in targeted radiopharmaceutical therapies, addressing significant unmet needs in metastatic castration-resistant prostate cancer (mCRPC). The differentiated profile of TLX591-Tx, including its intensified dosing schedule and manageable safety profile, positions it favorably against competitors in the space.

What we're watching

Clinical Validation: How the peer-reviewed results will influence regulatory approval prospects for TLX591-Tx.
Theranostic Approach: Whether the combination of PSMA-PET imaging and TLX591-Tx therapy can sustain its clinical differentiation in real-world settings.
Market Positioning: The pace at which Telix can commercialize TLX591-Tx if the Phase 3 ProstACT Global study succeeds.